Verve Therapeutics Announces Leadership Update
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Troy Lister, Ph.D., currently serving as Verve’s senior vice president, research and early development, has been appointed chief scientific officer (CSO), effective June 21, 2024. Andrew Bellinger, M.D., Ph.D., who has served as CSO since 2019, will step down from this role and serve in an advisory capacity.
- Andrew Bellinger, M.D., Ph.D., who has served as CSO since 2019, will step down from this role and serve in an advisory capacity.
- “Over the past two years, Troy has been a respected colleague and wonderful leader at Verve, preceded by a longstanding career in research and development and program and portfolio management.
- Prior to joining Verve, he served as senior vice president of research and development at Spero Therapeutics, where he helped build the research and development organization and led multiple programs into first-in-human studies and through early clinical development.
- Dr. Lister has also held scientific and leadership roles at the Novartis Institutes for Biomedical Research and AstraZeneca.